drugset / Trial / NCT07704697

Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan

NCT07704697

Phase 3 Completed 346 enrolled Shenzhen Salubris Pharmaceuticals Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main objective of the study will be to assess the efficacy and safety of Sacubitril/Allisartan (240mg) and Amlodipine (5mg) in patients with essential hypertension uncontrolled after 4-week treatment with Sacubitril/Allisartan (240mg).

Timeline

Start
2024-11-23
Primary completion
2025-11-10
Completion
2025-11-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg
Background Sacubitril Small molecule 240 mg